Live Breaking News & Updates on 000 People Are Diagnosed With Renal Cell Carcinoma Each Year In Line Government Policy Supporting Wider Geographic Access To Nuclear Medicine

MELBOURNE, Australia, Aug. 2, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of China with its strategic partner Grand Pharmaceutical Group Limited (Grand Pharma). TLX591-CDx (Illuccix) for prostate cancer imaging China: An Investigational New Drug (IND) application has been submitted by Telix's partner in Greater China, Grand Pharma, to the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) - and accepted for review - for a pivotal Phase III registration study that will bridge to the United States Food and Drug Administration (FDA) approval of Illuccix. South Korea: As previously reported, an imported New Drug Application (NDA) has been submitted by Telix's partner in South Korea, DuChemBio Co, Ltd. (DuChemBio), to the Minist ....

United States , South Korea , Cdx Illuccix , Kyahn Williamson , Davidn Cade , Telix Asia Pacific , Asia Pacific , Christian Behrenbruch , Telix Pharmaceuticals , Drug Administration , Australian Securities Exchange , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Group Limited Grand Pharma , Corporate Communications , Duchembio Co Ltd , National Medical Products Administration , Ministry Of Food , Pharmaceuticals Limited , Operating Region , Grand Pharmaceutical Group Limited , Grand Pharma , Greater China , Drug Evaluation , United States Food , New Drug Application ,